journal
https://read.qxmd.com/read/33460574/palbociclib-with-adjuvant-endocrine-therapy-in-early-breast-cancer-pallas-interim-analysis-of-a-multicentre-open-label-randomised-phase-3-study
#1
Erica L Mayer, Amylou C Dueck, Miguel Martin, Gabor Rubovszky, Harold J Burstein, Meritxell Bellet-Ezquerra, Kathy D Miller, Nicholas Zdenkowski, Eric P Winer, Georg Pfeiler, Matthew Goetz, Manuel Ruiz-Borrego, Daniel Anderson, Zbigniew Nowecki, Sibylle Loibl, Stacy Moulder, Alistair Ring, Florian Fitzal, Tiffany Traina, Arlene Chan, Hope S Rugo, Julie Lemieux, Fernando Henao, Alan Lyss, Silvia Antolin Novoa, Antonio C Wolff, Marcus Vetter, Daniel Egle, Patrick G Morris, Eleftherios P Mamounas, Miguel J Gil-Gil, Aleix Prat, Hannes Fohler, Otto Metzger Filho, Magdalena Schwarz, Carter DuFrane, Debora Fumagalli, Kathy Puyana Theall, Dongrui Ray Lu, Cynthia Huang Bartlett, Maria Koehler, Christian Fesl, Angela DeMichele, Michael Gnant
BACKGROUND: Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial aimed to investigate whether the addition of 2 years of palbociclib to adjuvant endocrine therapy improves invasive disease-free survival over endocrine therapy alone in patients with hormone-receptor-positive, HER2-negative, early-stage breast cancer. METHODS: PALLAS is an ongoing multicentre, open-label, randomised, phase 3 study that enrolled patients at 406 cancer centres in 21 countries worldwide with stage II-III histologically confirmed hormone-receptor-positive, HER2-negative breast cancer, within 12 months of initial diagnosis...
January 15, 2021: Lancet Oncology
https://read.qxmd.com/read/33460573/cdk4-6-inhibition-in-early-stage-breast-cancer-how-far-is-it-from-becoming-standard-of-care
#2
Binghe Xu, Ying Fan
No abstract text is available yet for this article.
January 15, 2021: Lancet Oncology
https://read.qxmd.com/read/33453762/implications-of-the-new-eu-uk-trade-agreement-for-cancer-care
#3
Susan Mayor
No abstract text is available yet for this article.
January 14, 2021: Lancet Oncology
https://read.qxmd.com/read/33450184/surgery-for-malignant-pleural-mesothelioma-after-radiotherapy-smart-final-results-from-a-single-centre-phase-2-trial
#4
B C John Cho, Laura Donahoe, Penelope A Bradbury, Natasha Leighl, Shaf Keshavjee, Andrew Hope, Prodipto Pal, Michael Cabanero, Kasia Czarnecka, Karen McRae, Ming-Sound Tsao, Marc de Perrot
BACKGROUND: A novel approach for managing malignant pleural mesothelioma, surgery for mesothelioma after radiotherapy (SMART), consisting of a short accelerated course of high-dose, hemithoracic, intensity modulated radiotherapy (IMRT) followed by extrapleural pneumonectomy was developed. The aim of this study was to evaluate the clinical feasibility of the SMART protocol. METHODS: In this single-centre, phase 2 trial, patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, with histologically proven, resectable, cT1-3N0M0 disease who had previously untreated malignant pleural mesothelioma were eligible for inclusion...
January 12, 2021: Lancet Oncology
https://read.qxmd.com/read/33450183/smart-logical-radiotherapy-and-surgery-beyond-mars
#5
Harvey I Pass
No abstract text is available yet for this article.
January 12, 2021: Lancet Oncology
https://read.qxmd.com/read/33444529/ultra-hypofractionated-versus-conventionally-fractionated-radiotherapy-for-prostate-cancer-hypo-rt-pc-patient-reported-quality-of-life-outcomes-of-a-randomised-controlled-non-inferiority-phase-3-trial
#6
Per Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, Lars Beckman, Björn Tavelin, David Norman, Camilla Thellenberg-Karlsson, Morten Hoyer, Magnus Lagerlund, Jon Kindblom, Claes Ginman, Bengt Johansson, Kirsten Björnlinger, Mihajl Seke, Måns Agrup, Björn Zackrisson, Elisabeth Kjellén, Lars Franzén, Anders Widmark
BACKGROUND: The HYPO-RT-PC trial compared conventionally fractionated radiotherapy with ultra-hypofractionated radiotherapy in patients with localised prostate cancer. Ultra-hypofractionation was non-inferior to conventional fractionation regarding 5-year failure-free survival and toxicity. We aimed to assess whether patient-reported quality of life (QOL) differs between conventional fractionation and ultra-hypofractionation up to 6 years after treatment in the HYPO-RT-PC trial. METHODS: HYPO-RT-PC is a multicentre, open-label, randomised, controlled, non-inferiority, phase 3 trial done in 12 centres (seven university hospitals and five county hospitals) in Sweden and Denmark...
January 11, 2021: Lancet Oncology
https://read.qxmd.com/read/33357510/objective-responses-to-first-line-neoadjuvant-carboplatin-paclitaxel-regimens-for-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-icon8-post-hoc-exploratory-analysis-of-a-randomised-phase-3-trial
#7
Robert D Morgan, Iain A McNeish, Adrian D Cook, Elizabeth C James, Rosemary Lord, Graham Dark, Rosalind M Glasspool, Jonathan Krell, Christine Parkinson, Christopher J Poole, Marcia Hall, Dolores Gallardo-Rincón, Michelle Lockley, Sharadah Essapen, Jeff Summers, Anjana Anand, Abel Zachariah, Sarah Williams, Rachel Jones, Kate Scatchard, Axel Walther, Jae-Weon Kim, Sudha Sundar, Gordon C Jayson, Jonathan A Ledermann, Andrew R Clamp
BACKGROUND: Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic approach has been validated in randomised, phase 3 trials, evaluation of response to neoadjuvant chemotherapy using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST), and cancer antigen 125 (CA125) has not been reported. We describe RECIST and Gynecologic Cancer InterGroup (GCIG) CA125 responses in patients receiving platinum-based neoadjuvant chemotherapy followed by DPS in the ICON8 trial...
December 22, 2020: Lancet Oncology
https://read.qxmd.com/read/33357420/fixed-dose-combination-of-pertuzumab-and-trastuzumab-for-subcutaneous-injection-plus-chemotherapy-in-her2-positive-early-breast-cancer-federica-a-randomised-open-label-multicentre-non-inferiority-phase-3-study
#8
Antoinette R Tan, Seock-Ah Im, André Mattar, Ramon Colomer, Daniil Stroyakovskii, Zbigniew Nowecki, Michelino De Laurentiis, Jean-Yves Pierga, Kyung Hae Jung, Christian Schem, Alexandra Hogea, Tanja Badovinac Crnjevic, Sarah Heeson, Mahesh Shivhare, Whitney P Kirschbrown, Eleonora Restuccia, Christian Jackisch
BACKGROUND: A subcutaneous formulation of pertuzumab and trastuzumab with recombinant human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab, trastuzumab, and hyaluronidase-zzxf) was approved by the US Food and Drug Administration (FDA) on June 29, 2020. We report the primary analysis of the FeDeriCa study, which was designed to assess the pharmacokinetics, efficacy, and safety of the fixed-dose subcutaneous formulation compared to intravenous pertuzumab plus trastuzumab in patients with HER2-positive early breast cancer in the neoadjuvant-adjuvant setting...
December 17, 2020: Lancet Oncology
https://read.qxmd.com/read/33357419/results-from-the-federica-trial-are-we-reducing-the-burden-of-breast-cancer-treatment
#9
Rupert Bartsch, Christoph Minichsdorfer, Cornelia Kolberg-Liedtke
No abstract text is available yet for this article.
December 17, 2020: Lancet Oncology
https://read.qxmd.com/read/33341123/cuts-in-cancer-research-funding-due-to-covid-19
#10
Talha Khan Burki
No abstract text is available yet for this article.
December 17, 2020: Lancet Oncology
https://read.qxmd.com/read/33316218/conditional-recurrence-free-survival-of-clinical-complete-responders-managed-by-watch-and-wait-after-neoadjuvant-chemoradiotherapy-for-rectal-cancer-in-the-international-watch-wait-database-a-retrospective-international-multicentre-registry-study
#11
Laura M Fernandez, Guilherme P São Julião, Nuno L Figueiredo, Geerard L Beets, Maxime J M van der Valk, Renu R Bahadoer, Denise E Hilling, Elma Meershoek-Klein Kranenbarg, Annet G H Roodvoets, Andrew G Renehan, Cornelis J H van de Velde, Angelita Habr-Gama, Rodrigo O Perez
BACKGROUND: Watch and wait is a novel management strategy in patients with rectal cancer who have a clinical complete response after neoadjuvant chemoradiotherapy. Surveillance of these patients is generally intensive, because local regrowth (with the potential for salvage) occurs in 25% of patients, and distant metastases occur in 10% of patients. It is unclear for how long these patients should be followed up. To address this issue, we did conditional survival modelling using the International Watch & Wait Database (IWWD), which is a large-scale registry of patients with a clinical complete response after neoadjuvant chemotherapy who have been managed by a watch-and-wait strategy...
December 11, 2020: Lancet Oncology
https://read.qxmd.com/read/33301740/short-course-radiotherapy-followed-by-chemotherapy-before-total-mesorectal-excision-tme-versus-preoperative-chemoradiotherapy-tme-and-optional-adjuvant-chemotherapy-in-locally-advanced-rectal-cancer-rapido-a-randomised-open-label-phase-3-trial
#12
Renu R Bahadoer, Esmée A Dijkstra, Boudewijn van Etten, Corrie A M Marijnen, Hein Putter, Elma Meershoek-Klein Kranenbarg, Annet G H Roodvoets, Iris D Nagtegaal, Regina G H Beets-Tan, Lennart K Blomqvist, Tone Fokstuen, Albert J Ten Tije, Jaume Capdevila, Mathijs P Hendriks, Ibrahim Edhemovic, Andrés Cervantes, Per J Nilsson, Bengt Glimelius, Cornelis J H van de Velde, Geke A P Hospers
BACKGROUND: Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation (RAPIDO) trial aimed to reduce distant metastases without compromising locoregional control. METHODS: In this multicentre, open-label, randomised, controlled, phase 3 trial, participants were recruited from 54 centres in the Netherlands, Sweden, Spain, Slovenia, Denmark, Norway, and the USA...
December 7, 2020: Lancet Oncology
https://read.qxmd.com/read/33301738/efficacy-and-safety-of-oral-panobinostat-plus-subcutaneous-bortezomib-and-oral-dexamethasone-in-patients-with-relapsed-or-relapsed-and-refractory-multiple-myeloma-panorama-3-an-open-label-randomised-phase-2-study
#13
Jacob P Laubach, Fredrik Schjesvold, Mário Mariz, Meletios A Dimopoulos, Ewa Lech-Maranda, Ivan Spicka, Vania T M Hungria, Tatiana Shelekhova, Andre Abdo, Lutz Jacobasch, Chantana Polprasert, Roman Hájek, Árpád Illés, Tomasz Wróbel, Anna Sureda, Meral Beksac, Iara Z Gonçalves, Joan Bladé, S Vincent Rajkumar, Ajai Chari, Sagar Lonial, Andrew Spencer, Pierre Maison-Blanche, Philippe Moreau, Jesus F San-Miguel, Paul G Richardson
BACKGROUND: Improved therapeutic options are needed for patients with relapsed or relapsed and refractory multiple myeloma. Subcutaneous bortezomib has replaced intravenous bortezomib as it is associated with a more favourable toxicity profile. We investigated the activity and safety of three different dosing regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone for this indication. METHODS: PANORAMA 3 is an open-label, randomised, phase 2 study being done at 71 sites (hospitals and medical centres) across 21 countries...
December 4, 2020: Lancet Oncology
https://read.qxmd.com/read/33285097/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum-etoposide-alone-in-first-line-treatment-of-extensive-stage-small-cell-lung-cancer-caspian-updated-results-from-a-randomised-controlled-open-label-phase-3-trial
#14
Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay V Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares
BACKGROUND: First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone. METHODS: CASPIAN is an ongoing, open-label, sponsor-blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 countries worldwide...
December 4, 2020: Lancet Oncology
https://read.qxmd.com/read/33278913/estro-2020-online-congress
#15
Allison Landman
No abstract text is available yet for this article.
December 3, 2020: Lancet Oncology
https://read.qxmd.com/read/33278912/reporting-cancer-care-outcomes-from-the-private-sector
#16
Talha Khan Burki
No abstract text is available yet for this article.
December 3, 2020: Lancet Oncology
https://read.qxmd.com/read/33253642/covid-19-and-systemic-anticancer-therapy-exploiting-uncertainty
#17
Hans Gelderblom, Hendrik Veelken, Anne M Stiggelbout
No abstract text is available yet for this article.
November 27, 2020: Lancet Oncology
https://read.qxmd.com/read/33253641/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial
#18
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, Neal D Shore, Leonard G Gomella, Ashish M Kamat, Trinity J Bivalacqua, Jeffrey S Montgomery, Seth P Lerner, Joseph E Busby, Michael Poch, Paul L Crispen, Gary D Steinberg, Anne K Schuckman, Tracy M Downs, Robert S Svatek, Joseph Mashni, Brian R Lane, Thomas J Guzzo, Gennady Bratslavsky, Lawrence I Karsh, Michael E Woods, Gordon Brown, Daniel Canter, Adam Luchey, Yair Lotan, Tracey Krupski, Brant A Inman, Michael B Williams, Michael S Cookson, Kirk A Keegan, Gerald L Andriole, Alexander I Sankin, Alan Boyd, Michael A O'Donnell, David Sawutz, Richard Philipson, Ruth Coll, Vikram M Narayan, F Peter Treasure, Seppo Yla-Herttuala, Nigel R Parker, Colin P N Dinney
BACKGROUND: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer. METHODS: In this phase 3, multicentre, open-label, repeat-dose study done in 33 centres (hospitals and clinics) in the USA, we recruited patients aged 18 years or older, with BCG-unresponsive non-muscle-invasive bladder cancer and an Eastern Cooperative Oncology Group status of 2 or less...
November 27, 2020: Lancet Oncology
https://read.qxmd.com/read/33253640/nadofaragene-firadenovec-a-new-gold-standard-for-bcg-unresponsive-bladder-cancer
#19
Girish S Kulkarni
No abstract text is available yet for this article.
November 27, 2020: Lancet Oncology
https://read.qxmd.com/read/33253639/the-effect-of-clinical-decision-making-for-initiation-of-systemic-anticancer-treatments-in-response-to-the-covid-19-pandemic-in-england-a-retrospective-analysis
#20
James J Clark, Dominic Dwyer, Nina Pinwill, Peter Clark, Peter Johnson, Allan Hackshaw
BACKGROUND: Cancer services worldwide had to adapt in response to the COVID-19 pandemic to minimise risk to patients and staff. We aimed to assess the national impact of COVID-19 on the prescribing of systemic anticancer treatment in England, immediately after lockdown and after the introduction of new treatments to reduce patient risk. METHODS: We did a retrospective analysis using data from a central National Health Service England web database mandated for clinicians to register intention to start all new systemic anticancer treatments approved for use in England since 2016...
November 27, 2020: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"